Stephen MD - Biotron Chief Officer

All Insiders . USA . 
Stock . Biotron Limited . Stakeholders . Insider . Stephen MD
BITRF Stock  USD 0.01  0.00  0.00%   

Insider

Stephen MD is Chief Officer of Biotron Limited
Phone61 2 9300 3344
Webhttps://www.biotron.com.au

Biotron Management Efficiency

The company has return on total asset (ROA) of (0.5574) % which means that it has lost $0.5574 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1224) %, meaning that it generated substantial loss on money invested by shareholders. Biotron's management efficiency ratios could be used to measure how well Biotron manages its routine affairs as well as how well it operates its assets and liabilities.
Biotron Limited has accumulated 77.24 K in total debt with debt to equity ratio (D/E) of 0.07, which may suggest the company is not taking enough advantage from borrowing. Biotron Limited has a current ratio of 2.3, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Biotron until it has trouble settling it off, either with new capital or with free cash flow. So, Biotron's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biotron Limited sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biotron to invest in growth at high rates of return. When we think about Biotron's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Paul CPAMosaic Immunoengineering
55
Ron HebertCovalon Technologies
N/A
Elaine ZhangCovalon Technologies
N/A
Jean EpinatCellectis SA
N/A
Kyung NamWortmanCellectis SA
53
Cyril EmpigMosaic Immunoengineering
N/A
Marvin MDMosaic Immunoengineering
79
Jay CarlsonMosaic Immunoengineering
N/A
Gerry ArambulaCovalon Technologies
N/A
Nicole SteinmetzMosaic Immunoengineering
43
Dr MBACellectis SA
46
Joseph MPHMosaic Immunoengineering
50
Simon SmithCovalon Technologies
N/A
Hamed AbbasianCovalon Technologies
N/A
Pascalyne WilsonCellectis SA
N/A
Greg LeszczynskiCovalon Technologies
N/A
Valerie CrosCellectis SA
N/A
Steven KingMosaic Immunoengineering
59
MSc MScCellectis SA
54
Mark DoolittleCovalon Technologies
N/A
Jason GorelCovalon Technologies
N/A
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia. Biotron operates under Biotechnology classification in the United States and is traded on OTC Exchange. Biotron Limited [BITRF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Equity-1.12
Return On Asset-0.56

Biotron Limited Management Team

Elected by the shareholders, the Biotron's board of directors comprises two types of representatives: Biotron inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biotron. The board's role is to monitor Biotron's management team and ensure that shareholders' interests are well served. Biotron's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biotron's outside directors are responsible for providing unbiased perspectives on the board's policies.
BSc GCertAppFin, MD Director
CA BEcon, Company Sec
Stephen MD, Chief Officer

Biotron Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Biotron a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-1.12
Return On Asset-0.56
Profit Margin(1.78) %
Operating Margin(1.78) %
Current Valuation15.31 M
Shares Outstanding901.94 M
Shares Owned By Insiders14.13 %
Price To Earning(3.04) X
Price To Book23.61 X
Price To Sales11.17 X

Currently Active Assets on Macroaxis

ESRTEmpire State Realty
CCitigroup
CCitigroup
GOOGAlphabet Inc Class C
DDDupont De Nemours

Other Information on Investing in Biotron Pink Sheet

Biotron financial ratios help investors to determine whether Biotron Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotron with respect to the benefits of owning Biotron security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY